Objective: To directly compare the efficacy of methylphenidate and atomoxetine in improving symptoms, social functions, and quality of life among adults with ADHD. Method: This was an 8-to-10-week, open-label, head-to-head, randomized clinical trial with two treatment arms: immediate-release methylphenidate (IR-methylphenidate; n = 31) and atomoxetine once daily (n = 32). The outcome measures included ADHD symptom severity, quality of life, and functional impairments. Results: We found a significant reduction in overall ADHD symptoms and improvement in social functions and quality of life for both groups at Weeks 4 to 5 and Weeks 8 to 10. There was no significant difference in the slope of improvements over time except that atomoxetine was superior to IR-methylphenidate in reducing hyperactive/impulsive symptoms at Weeks 4 to 5. There was no significant group difference in the rates of adverse effects. Conclusion: Both IR-methylphenidate and atomoxetine are well tolerated and efficacious in ethnic Chinese adults with ADHD.
AdlerL. A.SpencerT.BrownT. E.HoldnackJ.SaylorK.SchuhK.KelseyD. (2009). Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: A 6-month, double-blind trial. Journal of Clinical Psychopharmacology, 29, 44-50.
2.
AdlerL. A.SpencerT. J.WilliamsD. W.MooreR. J.MichelsonD. (2008). Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: Final report of a 4-year study. Journal of Attention Disorders, 12, 248-253.
3.
AdlerL. A.ZimmermanB.StarrH. L.SilberS.PalumboJ.OrmanC.SpencerT. (2009). Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. Journal of Clinical Psychopharmacology, 29, 239-247.
4.
American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author.
5.
BarkleyR. A.MurphyK. R.DupaulG. I.BushT. (2002). Driving in young adults with attention deficit hyperactivity disorder: Knowledge, performance, adverse outcomes, and the role of executive functioning. Journal of the International Neuropsychological Society, 8, 655-672.
6.
BastiaensL. (2008). Both atomoxetine and stimulants improve quality of life in an ADHD population treated in a community clinic. Psychiatric Quarterly, 79, 133-137.
7.
BiedermanJ.FaraoneS. V. (2005). Attention-deficit hyperactivity disorder. Lancet, 366(9481), 237-248.
8.
BiedermanJ.FaraoneS. V.SpencerT. J.MickE.MonuteauxM. C.AleardiM. (2006). Functional impairments in adults with self-reports of diagnosed ADHD: A controlled study of 1001 adults in the community. Journal of Clinical Psychiatry, 67, 524-540.
9.
BiedermanJ.MonuteauxM. C.DoyleA. E.SeidmanL. J.WilensT. E.FerreroF.FaraoneS. V. (2004). Impact of executive function deficits and attention-deficit/hyperactivity disorder (ADHD) on academic outcomes in children. Journal of Consulting and Clinical Psychology, 72, 757-766.
10.
BrodM.JohnstonJ.AbleS.SwindleR. (2006). Validation of the adult attention-deficit/hyperactivity disorder quality-of-life scale (AAQoL): A disease-specific quality-of-life measure. Quality of Life Research, 15, 117-129.
11.
ChangL. R.ChiuY. N.WuY. Y.GauS. S. (2013). Father’s parenting and father-child relationship among children and adolescents with attention-deficit/hyperactivity disorder. Comprehensive Psychiatry, 54, 128-140. doi:10.1016/j.comppsych.2012.07.008
12.
ChaoC. Y.GauS. S.MaoW. C.ShyuJ. F.ChenY. C.YehC. B. (2008). Relationship of attention-deficit-hyperactivity disorder symptoms, depressive/anxiety symptoms, and life quality in young men. Psychiatry & Clinical Neurosciences, 62, 421-426.
13.
ChouW. J.ChouM. C.TzangR. F.HsuY. C.GauS. S.ChenS. J.ChengH. (2009). Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes. Psychiatry & Clinical Neurosciences, 63, 167-175.
14.
CoghillD. (2010). The impact of medications on quality of life in attention-deficit hyperactivity disorder: A systematic review. CNS Drugs, 24, 843-866.
15.
CoxD. J.MikamiA. Y.CoxB. S.ColemanM. T.MahmoodA.SoodA.MerkelR. L. (2008). Effect of long-acting OROS methylphenidate on routine driving in young adults with attention-deficit/hyperactivity disorder. Archives of Pediatrics & Adolescent Medicine, 162, 793-794.
16.
DanckaertsM.Sonuga-BarkeE. J.BanaschewskiT.BuitelaarJ.DopfnerM.HollisC.SteinhausenH. (2010). The quality of life of children with attention deficit/hyperactivity disorder: A systematic review. European Child & Adolescent Psychiatry, 19, 83-105.
17.
FalluA.RichardC.PrinzoR.BinderC. (2006). Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder. Current Medical Research & Opinion, 22, 2557-2566.
18.
FaraoneS. V.GlattS. J. (2010). A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. Journal of Clinical Psychiatry, 71, 754-763.
19.
FaraoneS. V.SpencerT.AleardiM.PaganoC.BiedermanJ. (2004). Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. Journal of Clinical Psychopharmacology, 24, 24-29.
20.
FriedmanS. R.RapportL. J.LumleyM.TzelepisA.VanVoorhisA.StettnerL.KakaatiL. (2003). Aspects of social and emotional competence in adult attention-deficit/hyperactivity disorder. Neuropsychology, 17, 50-58.
21.
GauS. S.ChenS. J.ChouW. J.ChengH.TangC. S.ChangH. L.HuangY. (2008). National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. Journal of Clinical Psychiatry, 69, 131-140.
22.
GauS. S.ChiangH. L. (2009). Sleep problems and disorders among adolescents with persistent and subthreshold attention-deficit/hyperactivity disorders. Sleep, 32, 671-679.
23.
GauS. S.ChongM. Y.ChenT. H.ChengA. T. (2005). A 3-year panel study of mental disorders among adolescents in Taiwan. American Journal of Psychiatry, 162, 1344-1350.
24.
GauS. S.ChongM. Y.YangP.YenC. F.LiangK. Y.ChengA. T. (2007). Psychiatric and psychosocial predictors of substance use disorders among adolescents: Longitudinal study. British Journal of Psychiatry, 190, 42-48.
25.
GauS. S.HuangY. S.SoongW. T.ChouM. C.ChouW. J.ShangC. Y.. . .LeeP. (2007). A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 17, 447-460.
26.
GauS. S.KesslerR. C.TsengW. L.WuY. Y.ChiuY. N.YehC. B.HwuH. G. (2007). Association between sleep problems and symptoms of attention-deficit/hyperactivity disorder in young adults. Sleep, 30, 195-201.
27.
GauS. S.NiH. C.ShangC. Y.SoongW. T.WuY. Y.LinL. Y.ChiuYN. (2010). Psychiatric comorbidity among children and adolescents with and without persistent attention-deficit hyperactivity disorder. Australian and New Zealand Journal of Psychiatry, 44, 135-143.
28.
GauS. S.ShangC. Y. (2010). Improvement of executive functions in boys with attention deficit hyperactivity disorder: An open-label follow-up study with once-daily atomoxetine. The International Journal of Neuropsychopharmacology, 13, 243-256.
29.
GauS. S.ShenH. Y.ChouM. C.TangC. S.ChiuY. N.GauC. S. (2006). Determinants of adherence to methylphenidate and the impact of poor adherence on maternal and family measures. Journal of Child and Adolescent Psychopharmacology, 16, 286-297.
30.
GauS. S.ShenH. Y.SoongW. T.GauC. S. (2006). An open-label, randomized, active-controlled equivalent trial of osmotic release oral system methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. Journal of Child and Adolescent Psychopharmacology, 16, 441-455.
31.
GauS. S.SoongW. T. (1999). Psychiatric comorbidity of adolescents with sleep terrors or sleepwalking: A case-control study. Australian and New Zealand Journal of Psychiatry, 33, 734-739.
32.
GreenhillL. L.PliszkaS.DulcanM. K.BernetW.ArnoldV.BeitchmanJ.KroegerK. (2001). Summary of the practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. Journal of the American Academy of Child & Adolescent Psychiatry, 40, 1352-1355.
33.
HantsonJ.WangP. P.Grizenko-VidaM.Ter-StepanianM.HarveyW.JooberR.GrizenkoN. (2011). Effectiveness of a therapeutic summer camp for children with ADHD: Phase I clinical intervention trial. Journal of Attention Disorders, 16, 610-617.
34.
HazellP. L.KohnM. R.DicksonR.WaltonR. J.GrangerR. E.WykG. W. (2011). Core ADHD symptom improvement with atomoxetine versus methylphenidate: A direct comparison meta-analysis. Journal of Attention Disorders, 15, 674-683.
35.
HechtmanL.AbikoffH.KleinR. G.WeissG.RespitzC.KouriJ.PollackS. (2004). Academic achievement and emotional status of children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. Journal of the American Academy of Child & Adolescent Psychiatry, 43, 812-819.
36.
JasinskiD. R.FariesD. E.MooreR. J.SchuhL. M.AllenA. J. (2008). Abuse liability assessment of atomoxetine in a drug-abusing population. Drug and Alcohol Dependence, 95, 140-146.
37.
KesslerR. C.AdlerL.AmesM.DemlerO.FaraoneS.HiripiE.WaltersE. E. (2005). The World Health Organization adult ADHD Self-Report Scale (ASRS): A short screening scale for use in the general population. Psychological Medicine, 35, 245-256.
38.
KratochvilC. J.HeiligensteinJ. H.DittmannR.SpencerT. J.BiedermanJ.WernickeJ.MichelsonD. (2002). Atomoxetine and methylphenidate treatment in children with ADHD: A prospective, randomized, open-label trial. Journal of the American Academy of Child & Adolescent Psychiatry, 41, 776-784.
39.
MattesJ. A.BoswellL.OliverH. (1984). Methylphenidate effects on symptoms of attention deficit disorder in adults. Archives of General Psychiatry, 41, 1059-1063.
40.
MatzaL. S.Van BruntD. L.CatesC.MurrayL. T. (2011). Test—Retest reliability of two patient-report measures for use in adults with ADHD. Journal of Attention Disorders, 15, 557-563.
41.
MaziadeM.RouleauN.LeeB.RogersA.DavisL.DicksonR. (2009). Atomoxetine and neuropsychological function in children with attention-deficit/hyperactivity disorder: Results of a pilot study. Journal of Child and Adolescent Psychopharmacology, 19, 709-718.
42.
MichelsonD.AdlerL.SpencerT.ReimherrF. W.WestS. A.AllenA. J.MiltonD. (2003). Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies. Biological Psychiatry, 53, 112-120.
43.
NewcornJ. H.KratochvilC. J.AllenA. J.CasatC. D.RuffD. D.MooreR. J.Atomoxetine/Methylphenidate Comparative Study Group. (2008). Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: Acute comparison and differential response. American Journal of Psychiatry, 165, 721-730.
44.
RetzW.RoslerM.OseC.ScheragA.AlmB.PhilipsenA.AmmerR. (2012). Multiscale assessment of treatment efficacy in adults with ADHD: A randomized placebo-controlled, multi-centre study with extended-release methylphenidate. World Journal of Biological Psychiatry, 13, 48-59.
45.
ShangC. Y.GauS. S. (2012). Improving visual memory, attention, and school function with atomoxetine in boys with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 22, 353-363.
46.
SingerJD. (1998). Using SAS PROC mixed to fit multilevel models, hierarchical models, and individual growth models. Journal of Educational and Behavioral Statistics, 23, 323-355.
47.
SpencerT. J.AdlerL. A.MeihuaQ.SaylorK. E.BrownT. E.HoldnackJ. A.KelseyD. K. (2010). Validation of the adult ADHD investigator symptom rating scale (AISRS). Journal of Attention Disorders, 14, 57-68.
48.
SpencerT. J.AdlerL. A.WeislerR. H.YouchaS. H. (2008). Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: A randomized, double-blind, multicenter, placebo-controlled study. Journal of Clinical Psychiatry, 69, 1437-1448.
49.
SpencerT. SBiedermanJ.WilensT.PrinceJ.HatchM.JonesJ.LarryS. (1998). Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. American Journal of Psychiatry, 155, 693-695.
50.
SteinM. A.WaldmanI. D.CharneyE.AryalS.SableC.GruberR.NewcornJ. H. (2011). Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts. Journal of Child and Adolescent Psychopharmacology, 21, 581-588.
51.
TakahashiM.GotoT.TakitaY.ChungS. K.WangY. F.GauS. S. (2014). An open-label, dose-titration tolerability study of atomoxetine hydrochloride in Korean, Chinese and Taiwanese adults with attention-deficit/hyperactivity disorder. Asia-Pacific Psychiatry, 6, 62-70.
52.
WangY.ZhengY.DuY.SongD. H.ShinY. J.ChoS. C.LevineL. R. (2007). Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: A randomized, double-blind comparison trial. Australian and New Zealand Journal of Psychiatry, 41, 222-230.
53.
WehmeierP. M.SchachtA.EscobarR.SavillN.HarpinV. (2010). Differences between children and adolescents in treatment response to atomoxetine and the correlation between health-related quality of life and Attention Deficit/Hyperactivity Disorder core symptoms: Meta-analysis of five atomoxetine trials. Child and Adolescent Psychiatry and Mental Health, 4, 30.
54.
WeissM. D.GibbinsC.GoodmanD. W.HodgkinsP. S.LandgrafJ. M.FaraoneS. V. (2010). Moderators and mediators of symptoms and quality of life outcomes in an open-label study of adults treated for attention-deficit/hyperactivity disorder. Journal of Clinical Psychiatry, 71, 381-390.
55.
WenderP. H.ReimherrF. W.WoodD.WardM. (1985). A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults. American Journal of Psychiatry, 142, 547-552.
56.
YehC. B.GauS. S.KesslerR. C.WuY. Y. (2008). Psychometric properties of the Chinese version of the adult ADHD Self-report Scale. International Journal of Methods in Psychiatric Research, 17, 45-54.
